M&A

News

Sanofi snaps up Inhibrx and its rare disease drug for $2.2bn

A slew of pharma mergers and acquisitions in the first month of 2024 has continued with a $2.2 billion play by Sanofi for Inhibrx and its clinical-stage drug candidate for

News

Sun Pharma reaches deal to buy out Taro in $347m deal

India’s Sun Pharma has signed an agreement to take full control of Israeli generic drugmaker Taro Pharmaceutical Industries, taking it into private hands.

News

Update: Orion buys stake in LegoChem as biotech push goes on

Food group Orion Group has taken a 25% in South Korean biotech LegoChem Bioscience, becoming its largest shareholder, as part of a push into the biotech sector.

News

As Novartis backs off, Amgen said to be after Cytokinetics

Speculation about a takeover play for Cytokinetics isn’t going away, with Amgen the latest company to be linked to the company and its highly-anticipated cardiovascular dr

R&D

Nine for 2024, Pt 2: Phase change and the challenges of scal...

In the first segment of Nine for 2024, we examined the continued fragility of healthcare systems, global pharmaceutical market infrastructure, and the journey to greater resilience.

News

Alphabet spinout SandboxAQ buys Good Chemistry

Two years after spinning out of the Google parent Alphabet, quantum computing and artificial intelligence specialist SandboxAQ has bought one of its smaller rivals in a de

Sanofi snaps up Inhibrx and its rare disease drug for $2.2bn

Sun Pharma reaches deal to buy out Taro in $347m deal

Update: Orion buys stake in LegoChem as biotech push goes on

As Novartis backs off, Amgen said to be after Cytokinetics

Nine for 2024, Pt 2: Phase change and the challenges of scal...

Alphabet spinout SandboxAQ buys Good Chemistry

Are Makary's priority review vouchers about to be canned?

Securing your ROI: Turning post-acquisition integration into...

M&A

Editor's Picks